Evidence map›Paper›PMID 28707077›Full record

ArticleEuropean journal of clinical pharmacology2017

Association of ABCB1 promoter methylation with aspirin exposure, platelet function, and clinical outcomes in Chinese intracranial artery stenosis patients.

Xingang Li, Kun Zhao, Ning Ma, Shusen Sun, Zhongrong Miao, Zhigang Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Obesity and Altered Aspirin Pharmacology.Clinical pharmacokinetics · 2018
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xingang LiDepartment of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Kun ZhaoDepartment of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ning MaDepartment of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, National Clinical Research Center for Neurological Diseases, Beijing, China.
Shusen SunCollege of Pharmacy, Western New England University, Springfield, MA, USA. ssun@wne.edu.
Zhongrong MiaoDepartment of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, National Clinical Research Center for Neurological Diseases, Beijing, China. zhongrongm@163.com.
Zhigang ZhaoDepartment of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 1022zzg@sina.com.

Funding

Capital Medical University 16JL72National Natural Science Foundation of China 81503157Organization Department of Beijing Municipal Committee 2014000021469G258
6 · The paper itself

Abstract

purposeDNA methylation typically acts to repress gene transcription. ABCB1 is involved in the intestinal absorption of aspirin. We aimed to investigate the impact of methylation status of ABCB1 promoter on aspirin exposure, platelet function, and clinical outcomes in Chinese intracranial artery stenosis patients receiving antiplatelet treatment.

methodsSymptomatic intracranial artery stenosis patients (without carrying CYP2C19 loss-of-function alleles) receiving antiplatelet therapy were enrolled in this study. The clinical outcome was the composite events, vascular death, recurrent ischemic stroke, myocardial infarction, or transit ischemic attack. Patients were divided into cases and controls based on the 1-year follow-up. Venous blood samples were collected for methylation level analysis, drug determination, and thromboelastographic assay. The Pearson correlation analysis was used to investigate the association of potential influencing factors and visualize them using three-dimensional plot. Receiver operator curves were applied to compare the diagnostic performance of potential factors and calculate the cut-off values.

resultsWe assessed 438 patients, 30 (non-carrier of CYP2C19 loss-of-function alleles) experienced adverse clinical events, and 30 patients without clinical events were selected as controls. Total of 34 CpG methylation sites were investigated for ABCB1 methylation. Compared with controls, the cases had significant lower methylation levels (CpG21.22), lower salicylic acid concentration, and lower arachidonic acid inhibition (P value < 0.05). A cut-off point of CpG21.22 0.015 was identified with a specificity of 0.759.

conclusionABCB1 hypomethylation is associated with lower drug absorption, higher platelet reactivity, and an increased risk of ischemic events in our patients. This may provide important insights into the research of aspirin resistance.

Indexed as

Arterial Occlusive DiseasesAspirinATP Binding Cassette Transporter, Subfamily BCase-Control StudiesDNA MethylationHumansIntracranial Arterial DiseasesPlatelet Aggregation InhibitorsPromoter Regions, GeneticThrombelastographyABCB1 protein, humanAspirinATP Binding Cassette Transporter, Subfamily BPlatelet Aggregation InhibitorsABCB1AspirinIschemic eventsMethylationSalicylic acidThromboelastography

Identifiers

PMID28707077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.